BidaskClub Upgrades ADMA Biologics (NASDAQ:ADMA) to “Buy”

BidaskClub upgraded shares of ADMA Biologics (NASDAQ:ADMA) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning, BidAskClub reports.

Several other research firms have also recently weighed in on ADMA. Dawson James cut shares of ADMA Biologics from a buy rating to a neutral rating and set a $4.00 price target for the company. in a research note on Monday, August 12th. HC Wainwright reaffirmed a buy rating and set a $13.00 price target on shares of ADMA Biologics in a research report on Wednesday, November 20th. Maxim Group set a $12.00 price objective on ADMA Biologics and gave the company a buy rating in a report on Monday, October 21st. Finally, ValuEngine upgraded ADMA Biologics from a hold rating to a buy rating in a research report on Friday, September 20th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $10.20.

Shares of ADMA stock opened at $4.36 on Tuesday. The company’s 50-day moving average price is $4.55 and its 200-day moving average price is $4.22. The company has a debt-to-equity ratio of 2.33, a current ratio of 6.42 and a quick ratio of 3.76. ADMA Biologics has a twelve month low of $2.08 and a twelve month high of $6.31.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.04. ADMA Biologics had a negative net margin of 260.92% and a negative return on equity of 203.21%. The firm had revenue of $7.22 million during the quarter, compared to analysts’ expectations of $5.71 million. Equities research analysts forecast that ADMA Biologics will post -0.87 earnings per share for the current year.

Hedge funds have recently modified their holdings of the company. Private Advisors LLC purchased a new position in shares of ADMA Biologics during the 2nd quarter worth approximately $41,000. Parametric Portfolio Associates LLC purchased a new position in ADMA Biologics in the second quarter valued at $49,000. Tower Research Capital LLC TRC grew its stake in ADMA Biologics by 13,268.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,368 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 13,268 shares in the last quarter. Voya Investment Management LLC grew its stake in ADMA Biologics by 60.4% during the 3rd quarter. Voya Investment Management LLC now owns 18,688 shares of the biotechnology company’s stock worth $83,000 after purchasing an additional 7,038 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY purchased a new stake in ADMA Biologics during the 3rd quarter worth about $85,000. Hedge funds and other institutional investors own 62.75% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

Read More: Google Finance Portfolio

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.